Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) Self-amplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP)

Fangjun Luo1†, Lina Zheng2†, Yue Hu3, Shuxian Liu3, Yan Wang3, Zhongkui Xiong4†, Xin Hu5* and Feng Tan3*

1 Department of Clinical Laboratory, Zhuji People’s Hospital, Zhuji, China, 2 Institute of Stem Cell and Tissue Engineering, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China, 3 Department of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China, 4 Department of Radiation Oncology, Shaoxing Second Hospital, Shaoxing, China, 5 Department of Basic Laboratory Medicine, School of Medical Laboratory Science and School of Life Science, Wenzhou Medical University, Wenzhou, China

RNA-based vaccine represents an irresistible and safe immunization strategy with decreasing theoretical risks of genomic integration and malignant cell transformation. To our knowledge, however, there is no report about development of RNA vaccine against Toxoplasma gondii infection. We have previously demonstrated that the recombinant T. gondii nucleoside triphosphate hydrolase-II (NTPase-II) protein is able to provide protective Th1 cell-mediated immunity against T. gondii. Herein, we evaluated the immunogenic potential of a self-amplifying RNA vaccine-encoding T. gondii NTPase-II gene, RREP-NTPase-II, delivered by a synthetic lipid nanoparticle (LNP). Immunization of mice with naked RREP-NTPase-II induced a strong cellular and humoral immune response with high-IgG antibody titers and IFN-γ production. The immunized mice displayed significantly prolonged survival time and reduction in brain parasite load (46.4%) compared with control group. Furthermore, mice vaccinated with RREP-NTPase-II-encapsulated LNP displayed significantly enhanced protection against acute infection as well as chronic infection with PRU cyst, which shows 62.1% reduction in brain cyst burden in comparison to control group. These results suggest that the combination of self-amplifying RNA and LNP ion would be beneficial to the development of a safe and long-acting vaccine against toxoplasmosis.

Keywords: Toxoplasma gondii, vaccine, nucleoside triphosphate hydrolase, self-amplifying RNA, lipid nanoparticle (LNP)
INTRODUCTION

Toxoplasma gondii, the pathogen of toxoplasmosis, is an obligate intracellular parasitic protozoan, which has a wide range of hosts including humans and warm-blooded animals (Cenci-Goga et al., 2011). Hosts could be infected through consumption of raw or undercooked meat of animals containing Toxoplasma cysts, or through ingestion of water or vegetables contaminated with Toxoplasma oocysts. Although T. gondii infection is usually asymptomatic in immunocompetent hosts, it is a serious threat to pregnant and immunocompromised individuals (Dubey, 2010).

Vaccines against Toxoplasma have been explored for a long time. However, ToxoVax, based on live attenuated S48 strain, is only one commercial vaccine for farm animals (Buxton and Innes, 1995). But it is unlikely to be applied to humans because of limitations of reduced efficacy as well as biosafety concerns (Zhang et al., 2013). To surmount this defect, current development trials of vaccines against T. gondii infection have been focused mainly on the subunit, recombinant, and nucleic acid vaccines (Jongert et al., 2009; Zhang et al., 2013). Among these different approaches, development of nucleic acid-based vaccine is a promising approach due to less expense, easiness to handle, as well as its ability to induce both humoral and cellular immune responses with low dose (Tang et al., 1992). To our knowledge, however, there is no report about development of RNA vaccine against T. gondii infection although plasmid-based DNA vaccines have been paid attention for several decades (Liu et al., 2012). The main obstacles to the development of RNA vaccine could be attributed to that RNA vaccine often elicits weak immune responses and requires multiple vaccinations because of the short intracellular half-life and easiness of degradation in vivo and during storage. Nonetheless, RNA-based vaccination still exhibits an irresistible advantage that RNA molecule exists solely in the cytoplasm, thereby extensively decreasing theoretical risks of genomic integration and malignant cell transformation, which give rise to safety concerns for DNA vaccines (Kofler et al., 2004). That is why RNA vaccination is not categorized as gene therapy by regulatory authorities. Thus far, the non-amplifying mRNA vaccines have been utilized in experimental animals for elicitation of humoral and cellular immune responses against tumor (Pascolo, 2008; Fotin-Mleczek et al., 2011), allergy (Weiss et al., 2012), and infectious disease (Lorenzi et al., 2010).

Recently, a self-amplifying RNA vector, pRREP, based on an alphavirus Semliki Forest virus (SFV) genome has been utilized to improve the weak immune responses induced by mRNA vaccines (Fleeton et al., 2001; Johansson et al., 2012). The skeleton of self-amplifying RNA mainly consists of the gene encoding the viral RNA replicase and the antigen of interest (AOI)-encoding mRNA, which replaces the viral structural protein gene. Upon transfection, the AOI would be plentifully expressed by the replicase complex amplification in the cytoplasm of the transfected cells (Karlsson and Liljestrom, 2004). In addition, this strategy avoids safety concerns and complicated operation because the RNA could be directly prepared by transcribing a linearized DNA plasmid using a T7 RNA polymerase in vitro (Johansson et al., 2012). Moreover, a synthetic lipid nanoparticle (LNP) delivery system has been utilized to deliver self-amplifying RNA in order to further enhance the vaccination efficiency in vivo (Geall et al., 2012; Hekele et al., 2013).

Toxoplasma gondii nucleoside triphosphate hydrolase (NTPase), accounting for 2–8% of the total protein of tachyzoites, has a potent apyrase activity and is released from dense granules into parasitophorous vacuole for successively degrading ATP to ADP and finally AMP (Asai et al., 1983; Nakaar et al., 1998). Two isoforms of NTPase have been verified in T. gondii. However, NTPase-I is expressed only in type I virulent strains, while NTPase-II generally exists in all strains (Asai et al., 1995). This difference indicates the possibility that NTPase-II might be more preferable as a potential vaccine candidate than NTPase-I, and this speculation is supported by the finding that the recombinant NTPase-II protein could elicit a strong specific Th1 immune response and partially protect the experimental mice from acute and chronic Toxoplasma infection (Tan et al., 2011).

In this study, we evaluated the potency of a self-amplifying RNA, RREP-NTPase-II, to induce specific immune response and protective efficiency anti-Toxoplasma challenge in BALB/c mice and tested further whether LNP delivery system effectively improves the immune response. We found that RREP-NTPase-II indeed elicited both humoral and cellular immune responses that could be enhanced by LNP encapsulation, indicating that the combination of self-amplifying RNA vaccine and LNP delivery system is a promising approach with an improved safety and immunogenicity profile.

MATERIALS AND METHODS

Mice

Female BALB/c mice and ICR mice (6–8 weeks old) were purchased from Laboratory Animal Center, Wenzhou Medical University, Zhejiang, China. They were bred and handled in strict accordance with the Good Animal Practice requirements of the Animal ethics Procedures and Guidelines of China. This research was approved by the Laboratory Animal Ethics Committee of Wenzhou Medical University (Permit number: wydw2015-0073). Humane endpoints are considered to avoid the mice pain or suffering via euthanasia. Mice were monitored daily for signs of toxoplasmosis, such as fatigue, difficulty in feeding and severe ascites. Mice shown above signs would be sacrificed immediately with CO2 gas.

Parasites

The cyst-forming type II strain PRU was maintained in female ICR mice. Forty-five days after infection, cysts were harvested from infected mouse brains for challenge of immunized mice. The virulent type I strain RH was routinely propagated in human foreskin fibroblast (HFF) as previously described (Li et al., 2016) and employed for acute challenge infection.

Plasmid Construction and RNA Synthesis

The DNA sequence of NTPase-II gene was amplified from the construct pBAD-HisB-NTPase-II (Tan et al., 2011)
using a set of specific primers 5′-TTCCGGGATGACAG TCTCAGTGCATTCC-3′ and 5′-CCACTAGTTTCAGATT GTGAGAATATCCGCGC-3′ and was inserted into Xma I and Spe I site of pRREP-eGFP (Karlsson and Liljestrom, 2004) to swap the coding sequence of eGFP. The resulting plasmid, pRREP-NTPase-II, was purified with E.Z.N.A.® Plasmid Mini Kit (OMEGA Bio-tek, USA) and stored at −20°C. Prior to immunization, the plasmids were linearized and RNAs in vitro transcription were made by using MEGAScript™ Kit (Ambion, USA) as described previously (Geall et al., 2012). Finally, the purified transcribed RNAs were capped with Vaccinia Capping System (NEB, USA) before encapsulation (Figure 1A).

Detection of Expression of NTPase-II

**In vitro**

The self-amplifying RNA was transfected into 293T cells at once post-transcription according to the manufacturer’s instructions of Lipofectamine® 2000 Reagent (Invitrogen, USA). Twenty-four hours after transfection, expression of NTPase-II was confirmed by indirect immunofluorescence assay (IFA) with the mouse

---

**FIGURE 1 | Characterization of self-amplifying RNA.** (A) Flow diagram of development of a self-amplifying RNA vaccine, RREP-NTPase-II, based on an alphavirus Semliki Forest virus (SFV) RNA vector. polyA, polyadenylation signal; 26S, the subgenomic promoter of SFV; eGFP, enhanced green fluorescent protein gene; NTPase-II, the full CDS of *Toxoplasma gondii* NTPase-II gene without the signal peptide; nSP1–4, the non-structural protein genes of SFV. (B) Immunofluorescence assay (IFA). The self-amplifying RNA was transiently transfected into 293T cells and the expression of NTPase-II was identified by IFA using specific-NTPase-II monoclonal antibody. Scale bars, 100 µm. (C) Western blot analysis. Cell lysates were separated by SDS–PAGE and NTPase-II was visualized using anti-NTPase-II monoclonal antibody. Recombinant NTPase-II (rNTPase-II) was loaded as positive control, cell lysates from either non-transfected cells (293T) or transfected with RREP-eGFP (RREP-eGFP) as negative control. (D) RNase protection evaluation. Before and after exposure to RNase A, RNA from either naked self-amplifying RNA or self-amplifying RNA encapsulated with lipid nanoparticle (LNP) was extracted and analyzed by RNA agarose gel electrophoresis.
monoclonal antibody anti-NTPase-II (1:2000 dilution) that has been raised in our laboratory (Tan et al., 2010) as the primary antibody. Finally, cells were stained with 0.5 µg/mL DAPI for 10 min and the fluorescent images were obtained with a fluorescence microscope (Nikon, Japan). Additionally, the expression of NTPase-II was further analyzed by Western blot using anti-NTPase-II monoclonal antibody. Cell lysates from either non-transfected or RREP-eGFP-transfected cells were used as a negative control, recombinant NTPase-II was used as a positive control.

Lipid Nanoparticle (LNP) Encapsulation of RNA

The preparation of LNP and encapsulation of RNA were identical with the previous description (Geall et al., 2012; Ma et al., 2014). Briefly, the LNP, consisting of 1,2-distearyl-sn-glycero-3-phosphocholine (DSPC, Sigma–Aldrich, USA), cholesterol (Sigma–Aldrich), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (ammonium salt) (PEG DMG 2000) (Avanti Polar Lipids, USA), and 1,2-dilinoleoyl-3-dimethylaminopropane (DLinDMA) synthesized as reported previously (Heyes et al., 2005) was produced by ethanol dilution process at 10:48:2:40 molar ratio (Geall et al., 2012). Then, the self-amplifying RNA vaccines dissolved in 100 mM citrate buffer were encapsulated in LNP by spontaneous vesicle formation process as previously described (Ma et al., 2014). The resulting RNA/LNP was dialyzed against PBS overnight at 4°C. The absorbance fell below 0.2. After washing three times with PBS plus 0.05% Tween 20 (PBST), the coated plates were blocked with 5% skim milk in PBST for at least 1 h at 37°C. Afterward, 100 µL of twofold serial dilution of serum samples from 1:100 in PBST solution were added and incubated for 1 h at 37°C. After washing, specific anti-NTPase-II total IgG or IgG isotype were detected by incubating plates with 100 µl of HRP-conjugated rabbit anti-mouse IgG, IgG1, or IgG2a (Invitrogen, USA) for 1 h at 37°C. The plate was washed extensively, and incubated with 100 µl of 3,3,5,5-tetramethylbenzidine (TMB). The reaction was stopped by adding 50 µl of 2.5 N H2SO4 after 10 min, and the optical density at 450 nm was detected with a microplate reader. Endpoint titers were calculated or at the dilution when the absorbance fell below 0.2.

Evaluation of Humoral Response

Specific anti-NTPase-II IgG antibody levels were measured by ELISA according to our previous description (Tan et al., 2011) with minor modifications. In brief, ELISA plates (Corning, USA) were coated overnight at 4°C with 5 µg/mL purified recombinant NTPase-II protein. After washing three times with PBS plus 0.05% Tween 20 (PBST), the coated plates were blocked with 5% skim milk in PBST for at least 1 h at 37°C. Afterward, 100 µL of twofold serial dilution of serum samples from 1:100 in PBST solution were added and incubated for 1 h at 37°C. After washing, specific anti-NTPase-II total IgG or IgG isotype were detected by incubating plates with 100 µl of HRP-conjugated rabbit anti-mouse IgG, IgG1, or IgG2a (Invitrogen, USA) for 1 h at 37°C. The plate was washed extensively, and incubated with 100 µl of 3,3,5,5-tetramethylbenzidine (TMB). The reaction was stopped by adding 50 µl of 2.5 N H2SO4 after 10 min, and the optical density at 450 nm was detected with a microplate reader. Endpoint titers were calculated or at the dilution when the absorbance fell below 0.2.

Evaluation of Cellular Response

Two weeks after the last booster immunization, five mice per group were sacrificed to obtain single splenocyte suspensions as described previously (Tan et al., 2011). After erythrocytes were lysed, the splenocytes were resuspended and plated in triplicate in 96-well plates (3 x 10^5 cells/well) in presence of 10 µg/ml recombinant NTPase-II proteins or in plain complete medium as negative control or 5 µg/ml ConA as positive control. Plates were incubated for 72 or 96 h at 37°C and 5% CO2. For lymphocyte proliferation assay, the stimulated splenocytes were cultured for 72 h, and the spleen lymphocyte proliferative activity was detected with CCK-8 reagent (Dojindo Laboratories; Kumamoto, Japan) in accordance to the manufacturer’s instruction. The absorbance at 450 nm was read, and then, the stimulation index (SI) was calculated as the ratio of the average OD_{450} value from recombinant NTBPase-II-stimulated cultures/the average OD_{450} value from cells with medium cultures.

For IFN-γ analysis, cell-free supernatants from the stimulated splenocytes were collected and the IFN-γ activity was analyzed at 96 h after stimulation. According to the manufacturer’s instructions of Mouse IFN-γ ELISA Ready-SET-Go!® (eBioscience, USA), their IFN-γ concentrations were determined by reference to a standard curve constructed with known amounts of mouse IFN-γ and the sensitivity limit was 15 pg/ml.

Challenge Infection

Two weeks after the last booster immunization, five mice per group were infected intraperitoneally with 10^7 tachyzoites of RH.
strain and observed for an additional 30 days. The survival time and the percentages of mice survived were recorded daily.

In addition, 10 mice of each group were orally challenged with 20 tissue cysts of PRU strain on day 35. Mortality was observed daily for 45 days, and the surviving mice were sacrificed for quantification of cysts in brain as described previously (Tan et al., 2011).

Statistical Analysis
Statistical analysis was carried out with one-way ANOVA and multiple comparison procedures using SPSS 13.0 software for each assay, and Kaplan–Meier test for survival analysis. Data were represented as the mean ± SEM. Differences were considered statistically significant when $p < 0.05$.

RESULTS
Detection of Expression of NTPase-II by IFA
Plasmid pRREP-NTPase-II as templates for transcription of RNA was constructed successfully by verification with sequencing (data not shown). For the assessment of protein expression in vitro, transfection of self-amplifying RNA into 293T cells was performed at once post-transcription and capping. At 24 h post-transfection, expression of the NTPase-II protein was verified by IFA with specific monoclonal antibody. The fluorescence was observed in the cells transfected with self-amplifying RNA, whereas no fluorescent signal was observed in the negative control (Figure 1B), demonstrating that NTPase-II protein could be expressed in mammalian cells. The identity of the expressed NTPase-II protein was further confirmed by Western blot. A single protein band was detected at the size of about 70 kDa corresponding to the predicted size of NTPase-II protein (Figure 1C).

RNA/LNP Vaccine Characterization
After RNA was encapsulated in LNP, characteristics of RREP-NTPase-II/LNP formulations were analyzed. For the assessment of encapsulation efficiency, the concentrations of both free RNA and total RNA in solution post-encapsulation were measured. The result showed that ~80% of the RNA was encapsulated. In addition, the integrity of encapsulated RNA was validated by denaturing agarose gel electrophoresis after treatment with RNase A (Figure 1D). The result showed that the encapsulated RNA was maintained, while the naked RNA was degraded by RNase A, demonstrating that the LNP has the ability to protect the encapsulated RNA from degradation.

Evaluation of the Humoral Immune Response
In order to evaluate if the immunization with self-amplifying RNA vaccine encoding NTPase-II antigen induced specific humoral immune response, the antibody titers in serum samples from immunized mice were detected by indirect ELISA 2 weeks after last vaccination. Results were presented as the mean of log_{10} titers ± SEM. As a result, a significantly higher NTPase-II-specific IgG titers were observed in groups immunized with RREP-NTPase-II (2.466 ± 0.206, $p < 0.001$) in contrast to three control groups, PBS (0.495 ± 0.040), RREP (0.60 ± 0.07), and RREP/LNP (0.656 ± 0.069; Figure 2A). In an additional experiment, the distribution of both IgG1 and IgG2a was also analyzed (Figures 2B,C). The levels of both IgG subtypes were significantly increased in mice immunized with RREP-NTPase-II ($p < 0.001$). Noteworthy, RREP-NTPase-II vaccine elicited slightly higher specific IgG2a (2.625 ± 0.174) levels when compared to IgG1 (1.59 ± 0.019), consistent with a Th1 response.

Furthermore, to investigate if LNP improved the humoral immune responses, mice were immunized with 10 µg of encapsulated RNA (RREP-NTPase-II/LNP). The encapsulated RNA elicited significantly higher total IgG (3.879 ± 0.173, $p < 0.001$) as well as both IgG subtypes titers, IgG1 (3.095 ± 0.106) and IgG2a (3.970 ± 0.094), than naked RNA (RREP-NTPase-II). Similarly, a Th1 response was elicited in immunized mice. These results indicate that the presence of LNP enhances the specific humoral immune response.

Evaluation of the Cellular Immune Responses
Two weeks after last vaccination, splenocytes were harvested from immunized mice and an in vitro lymphocyte proliferation assay was performed. Both RREP-NTPase-II (2.454 ± 0.221, $p < 0.001$) and RREP-NTPase-II/LNP (3.656 ± 0.317, $p < 0.001$) elicited a significantly higher SI values to the NTPase-II antigen stimulation. On the contrary, administration with PBS (1.098 ± 0.100), RREP (1.240 ± 0.129), or RREP/LNP (1.482 ± 0.143) induced low lymphocyte proliferation to NTPase-II stimulation (Figure 3A).

To further determine if immunization with self-amplifying RNA vaccine induced a cellular immune response, the concentration of IFN-γ in supernatants of splenocytes stimulated with NTPase-II antigen was measured. Upon stimulation, RREP-NTPase-II (214.10 ± 46.01) produced significantly higher levels of IFN-γ ($p < 0.001$). For RREP-NTPase-II/LNP (451.34 ± 16.26), the positive effect was even more pronounced and increased twofold than those from RREP-NTPase-II ($p < 0.01$). In contrast, neither the PBS control group (18.05 ± 1.98) nor the groups that immunized with RREP (16.59 ± 2.75) or RREP/LNP (23.64 ± 2.29) developed any detectable amount of IFN-γ (Figure 3B). These results suggest that RNA/LNP was able to elicit the antigen-specific IFN-γ-mediated responses.

Assessment of Protective Efficacy Against T. gondii Infection
To evaluate if self-amplifying RNA vaccine could confer effective protection against T. gondii acute infection, five mice per group were challenged with 10⁸ RH strain tachyzoites 2 weeks after boosting (Figure 4A). All mice immunized with PBS, RREP, or RREP/LNP died within 9 days after challenge. However, a significantly prolonged survival time was observed in mice
immunized with both RREP-NTPase-II and RREP-NTPase-II/LNP ($p < 0.01$). Especially in the RREP-NTPase-II/LNP group, one mouse still survived after 30 days of challenge, which showed the highest survival rate and was significantly higher than that of the RREP-NTPase-II group ($p < 0.01$).

Furthermore, the resistance to *T. gondii* chronic infection was also evaluated. The immunized mice were challenged with 20 PRU strain cysts 2 weeks after last immunization (Figure 4B). Forty-five days after the challenge, direct cyst counting was performed by optical microscopy in the brains of survived mice. Similar to the results of acute challenge, the number of brain cysts showed a significant reduction in both RREP-NTPase-II by 46.4% (1402.00 ± 225.50, $p < 0.05$) and RREP-NTPase-II/LNP by 62.1% (897.30 ± 98.22, $p < 0.01$) compared with PBS (2370.17 ± 310.36), RREP (2245.86 ± 319.89), or RREP/LNP (2231.67 ± 306.02). Therefore, immunization
vaccines are able to induce strong immune responses in cells, such as mature myocytes. Therefore, while many DNA vaccine strategies have been developed for inducing protective immunity against viral infection, to our knowledge, currently there is a popular view that the nuclear membrane of transfected cells is attributed to the major barrier for restriction of delivering DNA vaccine into nuclear and consequently reduction of the expression level of AOI (Dupuis et al., 2000). Particularly, it seems to be ineffective in non-dividing cells, such as mature myocytes. Therefore, while many DNA vaccines are able to induce strong immune responses in small animals, the immunity is generally weaker in larger animals, with the amount of DNA vaccine required for efficient immunity being 1,000-fold higher in larger species than in small animals (Kutzler and Weiner, 2008). In addition, although this limitation can be surmounted by immunizing more DNA and exploiting electroporation to promote the DNA transport from cytoplasm into nuclear (Dupuis et al., 2000), anti-vector immune response and hazard of vector chromosomal integration must be considered (Smerdou and Liljestrom, 1999; Koller et al., 2004). On the contrary, self-amplifying RNA vaccine employed in the present study circumvents these limitations due to its characteristics of strict cytoplasmic replication and expression, which improves the transfection efficient in different cell types, diminishes the need for codon modification, and excludes the risks of splicing and degradation (Johansson et al., 2012). To date, the vaccination of both naked or liposome-encapsulated non-amplifying mRNA (Weide et al., 2008, 2009; Rittig et al., 2011) and self-amplifying RNA packaged in viral replicon particles (VRPs; Bernstein et al., 2008, 2009) has been validated in human clinical trials for safety as well as increased cellular or humoral immunity. Herein, we have successfully constructed the self-amplifying RNA plasmid vaccine, pRREP-NTPase-II, and the expression of NTPase-II was verified by IFA and Western blot. Although we did not directly make a comparison between the self-amplifying RNA vaccine and DNA vaccine, we reasonably believe the self-amplifying RNA vaccine has several advantages than DNA vaccine because the lower dose of self-amplifying RNA vaccine (10 μg/time) and the less time of immunization (two times) can still elicit significant immune response in comparison with the conventional DNA vaccine, usually requires more than 100 μg plasmid per time and at least three times (Angus et al., 2000; Vercammen et al., 2000; Yuan et al., 2011).

In addition, in our study, the production and amplification of DNA templates for in vitro transcription were completed using standard molecular cloning techniques. The self-amplifying RNA was then transcribed in vitro using a commercial kit, which can produce up to milligram quantities of RNA. Compared with other mRNA vaccine, the production of the self-amplifying RNA not only eliminates the potential risks that produce infectious virus via recombination, but circumvents the immunity against viral vectors because the viral replicon is intrinsically able to induce apoptosis of the transfected cell, resulting in transient and self-eliminating expression of the self-amplifying RNA vaccine (Johanning et al., 1995; Berglund et al., 1998; Fleeton et al., 2001). Importantly, the self-amplifying RNA is able to induce both humoral and cellular immune responses as determined in the present study.

Currently, many kinds of adjuvants have been applied and reported to enhance immune responses and protection against T. gondii in a good deal of studies. However, to our knowledge, the LNP delivery system is not so far utilized as an adjuvant in the development of vaccines against T. gondii, even though it has been developed to encapsulate self-amplifying mRNA for eliciting specific immune responses against antigens from HIV (Geall et al., 2012) or influenza virus (Hekele et al., 2013).

with self-amplifying NTPase-II RNA encapsulated with LNP enhanced a substantial resistance to the acute and chronic challenges of T. gondii.

**DISCUSSION**

This study applies a RNA/LNP vaccination strategy, explored for inducing protective immunity against viral infection, to induce effective immune responses against T. gondii challenge. Significant information obtained demonstrates that a potent immune response could be induced by self-amplifying RNA, and this response can be further enhanced by LNP delivery system.

Currently, there is a popular view that the nuclear membrane of transfected cells is attributed to the major barrier for restriction of delivering DNA vaccine into nuclear and consequently reduction of the expression level of AOI (Dupuis et al., 2000). Particularly, it seems to be ineffective in non-dividing cells, such as mature myocytes. Therefore, while many DNA vaccines are able to induce strong immune responses in small animals, the immunity is generally weaker in larger animals, with the amount of DNA vaccine required for efficient immunity being 1,000-fold higher in larger species than in small animals (Kutzler and Weiner, 2008). In addition, although this limitation can be surmounted by immunizing more DNA and exploiting electroporation to promote the DNA transport from cytoplasm into nuclear (Dupuis et al., 2000), anti-vector immune response and hazard of vector chromosomal integration must be considered (Smerdou and Liljestrom, 1999; Koller et al., 2004). On the contrary, self-amplifying RNA vaccine employed in the present study circumvents these limitations due to its characteristics of strict cytoplasmic replication and expression, which improves the transfection efficient in different cell types, diminishes the need for codon modification, and excludes the risks of splicing and degradation (Johansson et al., 2012). To date, the vaccination of both naked or liposome-encapsulated non-amplifying mRNA (Weide et al., 2008, 2009; Rittig et al., 2011) and self-amplifying RNA packaged in viral replicon particles (VRPs; Bernstein et al., 2008, 2009) has been validated in human clinical trials for safety as well as increased cellular or humoral immunity. Herein, we have successfully constructed the self-amplifying RNA plasmid vaccine, pRREP-NTPase-II, and the expression of NTPase-II was verified by IFA and Western blot. Although we did not directly make a comparison between the self-amplifying RNA vaccine and DNA vaccine, we reasonably believe the self-amplifying RNA vaccine has several advantages than DNA vaccine because the lower dose of self-amplifying RNA vaccine (10 μg/time) and the less time of immunization (two times) can still elicit significant immune response in comparison with the conventional DNA vaccine, usually requires more than 100 μg plasmid per time and at least three times (Angus et al., 2000; Vercammen et al., 2000; Yuan et al., 2011).

In addition, in our study, the production and amplification of DNA templates for in vitro transcription were completed using standard molecular cloning techniques. The self-amplifying RNA was then transcribed in vitro using a commercial kit, which can produce up to milligram quantities of RNA. Compared with other mRNA vaccine, the production of the self-amplifying RNA not only eliminates the potential risks that produce infectious virus via recombination, but circumvents the immunity against viral vectors because the viral replicon is intrinsically able to induce apoptosis of the transfected cell, resulting in transient and self-eliminating expression of the self-amplifying RNA vaccine (Johanning et al., 1995; Berglund et al., 1998; Fleeton et al., 2001). Importantly, the self-amplifying RNA is able to induce both humoral and cellular immune responses as determined in the present study.

Currently, many kinds of adjuvants have been applied and reported to enhance immune responses and protection against T. gondii in a good deal of studies. However, to our knowledge, the LNP delivery system is not so far utilized as an adjuvant in the development of vaccines against T. gondii, even though it has been developed to encapsulate self-amplifying mRNA for eliciting specific immune responses against antigens from HIV (Geall et al., 2012) or influenza virus (Hekele et al., 2013).
In these studies, they have shown that the LNP encapsulation dramatically improves the potency of the self-amplifying RNA because the LNP delivery system might enhance transfection efficiency, prevent the RNA degradation from enzymes at the injection site, as well as boost antigen presenting cells to sequester RNA/LNP particles, thereby promoting antigen production and stimulating the innate immunity within these immune cells. In the present study, we have successfully encapsulated the self-amplifying RNA with LNP by an ethanol dilution process. Agarose gel electrophoresis determined that LNPs provide an effective protection of self-amplifying RNA from RNase A degradation.

As an obligate intracellular parasitic protozoan, Th1 cell-mediated immunity is considered to play a critical role in protective immunity to *T. gondii* (Jongert et al., 2009, 2010). IFN-γ, one of Th1-type cytokines, has been proven to be a pivotal mediator of resistance to *Toxoplasma in vivo* (Suzuki et al., 1988). Our previous studies (Tan et al., 2011) have demonstrated that the recombinant NTPase-II protein is able to provide protective Th1 cell-mediated immunity against *Toxoplasma* by induction of lymphocyte proliferation, high IFN-γ production, and activation of CD8+ T cells, the major T cell subset associated with acquired immune protection against *T. gondii* (Suzuki et al., 1989; Tan et al., 2011). Therefore, we paid more attention to assess the extent of cellular immune response using spleen lymphocytes from immunized mice. These results validated the significantly increased lymphocyte proliferation and IFN-γ level to *Toxoplasma* NTPase-II protein in mice immunized with naked self-amplifying RNA. More importantly, the enhanced lymphocyte proliferation response and higher IFN-γ production were promoted by LNP encapsulation. These findings indicate that immunization with naked self-amplifying RNA or LNP-encapsulated RNA indeed induces the IFN-γ-related Th1-type immunity, requiring for prevention of *Toxoplasma* infection, although more experiments should be designed to further evaluate the Th1-type immunity. Nevertheless, it is worth noticing that the immunity induced by RNA/LNP elicits a considerably higher protection rate than the naked self-amplifying RNA in experimental mice against *Toxoplasma* RH strain, significantly prolonging their surviving time up to 30 days after challenge. As a result, the higher survival rate and prolonged survival days further support that LNP encapsulation is better in inducing strong NTPase-II-specific IFN-γ production to sustain a protective immune response against *T. gondii*.

In addition, one advantage of self-amplifying RNA is the ability to elicit a significantly cellular memory immune response (Johansson et al., 2012). Although the memory T-cell immune responses were not investigated in the present study, the better control of brain cyst burden in both self-amplifying RNA-vaccinated mice groups during the chronic stage of toxoplasmosis, which is dependent on long-acting memory T cells, encourages us to speculate that self-amplifying RNA has the capability of eliciting an increase in effector memory T cells and the effect can be enhanced by LNP encapsulation. Also, the result consists with our previous finding that a significant decrease in brain cyst burden can be observed in mice vaccinated with NTPase-II protein, suggesting that *Toxoplasma* NTPase-II could be a potential vaccine candidate (Tan et al., 2011).

Although now it is not entirely clear to what extent the function of IgG antibodies is in anti-*Toxoplasma* infection, a widespread theory is that the specific IgG antibodies play a partial role in the resistance to *T. gondii* during secondary infection (Kang et al., 2000; Johnson and Sayles, 2002). In this study, therefore, the specific IgG antibodies were also detected in order to evaluate humoral immunity elicited by RNA vaccine. Expectedly, an enhanced anti-NTPase-II IgG response detected in sera from mice immunized with either naked self-amplifying RNA or RNA/LNP was validated. Furthermore, the serum IgG isotype profile was predominated by IgG2a, on behalf of a stronger Th1 cell-mediated immune responses, indicating that systemic humoral immunity elicited with RNA vaccine may involve in the prevention of *T. gondii* infection. More importantly, the IgG titers after vaccination with the RNA/LNP were superior to those induced by vaccination of naked RNA, which is consistent with previous findings that LNP encapsulation promotes a stronger Th1 cell response (Geall et al., 2012).

In summary, we have successfully encapsulated self-amplifying *T. gondii* NTPase-II RNA with LNP to produce RNA/LNP that can prevent the RNA degradation from RNase A. The naked self-amplifying RNA is capable to induce the protective NTPase-II-specific humoral and cellular immune responses to protect mice from *T. gondii* challenge. Additionally, RNA/LNP administered in the mouse enhances further the protective immunity. Noteworthy, although the partial protection was provided by this vaccine candidate, other effective immunization strategies and multi-antigens constructs should be included to produce better protective immunity in the future. In any case, the capability of the combination of self-amplifying RNA and LNP encapsulation to successfully elicit and extend protective immune response would be beneficial to the development of a safe and long-acting vaccine against *T. gondii* for future use in animals and humans.

**AUTHOR CONTRIBUTIONS**

FT conceived and designed the study. LZ and YH carried out plasmid construction and RNA synthesis. ZX prepared the lipid nanoparticle and encapsulated self-amplifying RNA. FL, SL, and YW performed immunization of mice and evaluation of protective immunity. FL and LZ analyzed the data and drafted the manuscript. XH and FT critically revised the manuscript. All authors read and approved the final manuscript.

**FUNDING**

This work was supported by Commonweal Technology Application Project Program of Zhejiang Province (2014C33161) and Commonweal Technology Application Project Program of Wenzhou City (Y20140665) to FTan, and College Students...
Science and Technology Innovation Activity and Xinminiao Talents Program of Zhejiang (2015R413061) to LZ. All funders had no role in the design of the study and collection, analysis, and interpretation of data as well as in writing the manuscript.

REFERENCES

Angus, C. W., Klivington-Evans, D., Dubey, J. P., and Kovacs, J. A. (2000). Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J. Infect. Dis. 181, 317–324. doi: 10.1086/315186

Asai, T., Miura, S., Sibley, L. D., Okabayashi, H., and Takeuchi, T. (1995). Biochemical and molecular characterization of nucleoside triphosphate hydrolase isozymes from the parasitic protozoan Toxoplasma gondii. J. Biol. Chem. 270, 11391–11397. doi: 10.1074/jbc.270.11.11391

Asai, T., O’Sullivan, W. J., and Tatsibana, M. (1993). A potent nucleoside triphosphate hydrolase from the parasitic protozoan Toxoplasma gondii. Purification, some properties, and activation by thiol compounds. J. Biol. Chem. 258, 6816–6822.

Berglund, P., Smerdou, C., Fleeton, M. N., Tubulekas, I., and Liljestrom, P. (1998). Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 16, 563–567. doi: 10.1038/nbt0898-563

Bernstein, D. I., Reap, E. A., Katen, K., Watson, A., Smith, K., Norberg, P., et al. (2016). A commercial vaccine for ovine toxoplasmosis. J. Infect. Dis. 214, 110(Suppl.), S11–S16. doi: 10.1093/infdis/jiw265

Bernstein, D. I., Reap, E. A., Katen, K., Watson, A., Smith, K., Norberg, P., et al. (2016). A commercial vaccine for ovine toxoplasmosis. J. Infect. Dis. 214, 110(Suppl.), S11–S16. doi: 10.1093/infdis/jiw265

Buxton, D., and Innes, E. A. (1995). A commercial vaccine for ovine toxoplasmosis. Parasitology 110(Suppl.), S11–S16. doi: 10.1017/S0031182000001418

Cenci-Goga, B. T., Rossitto, P. V., Sechi, P., McCrindle, C. M., and Cullor, J. S. (2013). Rapidly produced SAM vaccine against H7N9 influenza is immunogenic and protective in rodents. J. Immunol. 191, 1395–1398. doi: 10.1086/665797

Cenci-Goga, B. T., Rossitto, P. V., Sechi, P., McCrindle, C. M., and Cullor, J. S. (2013). Rapidly produced SAM vaccine against H7N9 influenza is immunogenic and protective in rodents. J. Immunol. 191, 1395–1398. doi: 10.1086/665797

D’Souza, S. (2010). Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells. Vaccine 28, 2556–2564. doi: 10.1016/j.vaccine.2010.01.031

Jongert, E., Lemiere, A., Van Ginderachter, J., De Craeye, S., Huygen, K., and Cullor, J. S. (2013). Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol. Ther. 19, 990–999. doi: 10.1038/mt.2010.289

Li, X., Chen, D. L., Hua, Q., Wan, Y., Zheng, L., Liu, Y., et al. (2016). Induction of Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Emerg. Microbes Infect. 5, 1–15. doi: 10.1038/emi.2013.54

Kuntje, M. A., and Weiner, D. B. (2008). DNA vaccines: ready for prime time? Nat. Rev. Genet. 9, 776–788. doi: 10.1038/nrg2342

Kloiber, A., and Weiner, D. B. (2008). DNA vaccines: ready for prime time? Nat. Rev. Genet. 9, 776–788. doi: 10.1038/nrg2342

Kloiber, A., and Weiner, D. B. (2008). DNA vaccines: ready for prime time? Nat. Rev. Genet. 9, 776–788. doi: 10.1038/nrg2342

Li, X., Chen, D. L., Hua, Q., Wan, Y., Zheng, L., Liu, Y., et al. (2016). Induction of Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Emerg. Microbes Infect. 5, 1–15. doi: 10.1038/emi.2013.54

Kloiber, A., and Weiner, D. B. (2008). DNA vaccines: ready for prime time? Nat. Rev. Genet. 9, 776–788. doi: 10.1038/nrg2342

Acknowledgment

We are grateful to Dr. Peter Liljestrom (Karolinska Institutet, Stockholm, Sweden) for the pPREP-eGFP construct.

ACKNOWLEDGMENT

We are grateful to Dr. Peter Liljestrom (Karolinska Institutet, Stockholm, Sweden) for the pPREP-eGFP construct.
Vercammen, M., Scorza, T., Huysgen, K., De Braekeleer, J., Diet, R., Jacobs, D., et al. (2000). DNA vaccination with genes encoding *Toxoplasma gondii* antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. *Infect. Immun.* 68, 38–45. doi: 10.1128/IAI.68.1.38-45.2000

Weide, B., Carralot, J. P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, L., et al. (2008). Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. *J. Immunother.* 31, 180–188. doi: 10.1097/CJI.0b013e31815ce501

Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., et al. (2009). Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. *J. Immunother.* 32, 498–507. doi: 10.1097/CJI.0b013e3181a00068

Weiss, R., Scheibelhofer, S., Roesler, E., Weinberger, E., and Thalhamer, J. (2012). mRNA vaccination as a safe approach for specific protection from type I allergy. *Expert Rev. Vaccines* 11, 55–67. doi: 10.1586/erv.11.168

Yuan, Z. G., Zhang, X. X., Lin, R. Q., Petersen, E., He, S., Yu, M., et al. (2011). Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding *Toxoplasma gondii* ROP18. *Vaccine* 29, 6614–6619. doi: 10.1016/j.vaccine.2011.06.110

Zhang, N. Z., Chen, J., Wang, M., Petersen, E., and Zhu, X. Q. (2013). Vaccines against *Toxoplasma gondii*: new developments and perspectives. *Expert Rev. Vaccines* 12, 1287–1299. doi: 10.1586/14760584.2013.844652

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Luo, Zheng, Hu, Liu, Wang, Xiong, Hu and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.